These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

656 related articles for article (PubMed ID: 28385948)

  • 61. Post-approval study of a highly pulsed, low-shear-rate, continuous-flow, left ventricular assist device, EVAHEART: a Japanese multicenter study using J-MACS.
    Saito S; Yamazaki K; Nishinaka T; Ichihara Y; Ono M; Kyo S; Nishimura T; Nakatani T; Toda K; Sawa Y; Tominaga R; Tanoue T; Saiki Y; Matsui Y; Takemura T; Niinami H; Matsumiya G;
    J Heart Lung Transplant; 2014 Jun; 33(6):599-608. PubMed ID: 24746637
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Multicentre clinical trial experience with the HeartMate 3 left ventricular assist device: 30-day outcomes.
    Zimpfer D; Netuka I; Schmitto JD; Pya Y; Garbade J; Morshuis M; Beyersdorf F; Marasco S; Rao V; Damme L; Sood P; Krabatsch T
    Eur J Cardiothorac Surg; 2016 Sep; 50(3):548-54. PubMed ID: 27436871
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE Registry.
    Zimpfer D; Gustafsson F; Potapov E; Pya Y; Schmitto J; Berchtold-Herz M; Morshuis M; Shaw SM; Saeed D; Lavee J; Heatley G; Gazzola C; Garbade J
    Eur Heart J; 2020 Oct; 41(39):3801-3809. PubMed ID: 33107561
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Implication of Preoperative Existence of Atrial Fibrillation on Hemocompatibility-Related Adverse Events During Left Ventricular Assist Device Support.
    Imamura T; Kinugawa K; Ono M; Kinoshita O; Fukushima N; Shiose A; Matsui Y; Yamazaki K; Saiki Y; Usui A; Niinami H; Matsumiya G; Arai H; Sawa Y
    Circ J; 2019 May; 83(6):1286-1292. PubMed ID: 31019163
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of left ventricular assist device implantation on mitral regurgitation: An analysis from the MOMENTUM 3 trial.
    Kanwar MK; Rajagopal K; Itoh A; Silvestry SC; Uriel N; Cleveland JC; Salerno CT; Horstmanshof D; Goldstein DJ; Naka Y; Bailey S; Gregoric ID; Chuang J; Sood P; Mehra MR
    J Heart Lung Transplant; 2020 Jun; 39(6):529-537. PubMed ID: 32279919
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Improved survival and decreasing incidence of adverse events with the HeartMate II left ventricular assist device as bridge-to-transplant therapy.
    John R; Kamdar F; Liao K; Colvin-Adams M; Boyle A; Joyce L
    Ann Thorac Surg; 2008 Oct; 86(4):1227-34; discussion 1234-5. PubMed ID: 18805167
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Propensity score-based analysis of long-term outcome of patients on HeartWare and HeartMate 3 left ventricular assist device support.
    Numan L; Ramjankhan FZ; Oberski DL; Oerlemans MIFJ; Aarts E; Gianoli M; Van Der Heijden JJ; De Jonge N; Van Der Kaaij NP; Meuwese CL; Mokhles MM; Oppelaar AM; De Waal EEC; Asselbergs FW; Van Laake LW
    ESC Heart Fail; 2021 Apr; 8(2):1596-1603. PubMed ID: 33635573
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Advanced heart failure treated with continuous-flow left ventricular assist device.
    Slaughter MS; Rogers JG; Milano CA; Russell SD; Conte JV; Feldman D; Sun B; Tatooles AJ; Delgado RM; Long JW; Wozniak TC; Ghumman W; Farrar DJ; Frazier OH;
    N Engl J Med; 2009 Dec; 361(23):2241-51. PubMed ID: 19920051
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Blood pressure and adverse events during continuous flow left ventricular assist device support.
    Saeed O; Jermyn R; Kargoli F; Madan S; Mannem S; Gunda S; Nucci C; Farooqui S; Hassan S; Mclarty A; Bloom M; Zolty R; Shin J; D'Alessandro D; Goldstein DJ; Patel SR
    Circ Heart Fail; 2015 May; 8(3):551-6. PubMed ID: 25870369
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Lessons learned from the first fully magnetically levitated centrifugal LVAD trial in the United States: the DuraHeart trial.
    Moazami N; Steffen RJ; Naka Y; Jorde U; Bailey S; Murali S; Camacho MT; Zucker M; Marascalco PJ; Rao V; Feldman D;
    Ann Thorac Surg; 2014 Aug; 98(2):541-7. PubMed ID: 24928670
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Left Ventricular Assist Device Flow Pattern Analysis Using a Novel Model Incorporating Left Ventricular Pulsatility.
    Grinstein J; Torii R; Bourantas CV; Garcia-Garcia HM
    ASAIO J; 2021 Jul; 67(7):724-732. PubMed ID: 33528162
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Omega-3 and hemocompatibility-related adverse events.
    Imamura T; Nguyen A; Rodgers D; Kim G; Raikhelkar J; Kalantari S; Narang N; Juricek C; Ota T; Jeevanandam V; Sayer G; Uriel N
    J Card Surg; 2020 Feb; 35(2):405-412. PubMed ID: 31850548
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Prediction of Survival After Implantation of a Fully Magnetically Levitated Left Ventricular Assist Device.
    Mehra MR; Nayak A; Morris AA; Lanfear DE; Nemeh H; Desai S; Bansal A; Guerrero-Miranda C; Hall S; Cleveland JC; Goldstein DJ; Uriel N; Chen L; Bailey S; Anyanwu A; Heatley G; Chuang J; Estep JD
    JACC Heart Fail; 2022 Dec; 10(12):948-959. PubMed ID: 36456068
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Third-generation continuous-flow left ventricular assist devices: a comparative outcome analysis by device type.
    Mihalj M; Heinisch PP; Schober P; Wieser M; Martinelli M; de By TMMH; Schefold JC; Luedi MM; Kadner A; Carrel T; Mohacsi P; Hunziker L; Reineke D
    ESC Heart Fail; 2022 Oct; 9(5):3469-3482. PubMed ID: 35880515
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Quality of life metrics in LVAD patients after hemocompatibility-related adverse events.
    Weber MP; Stulak J; Maltais S; Pagani FD; Cowger J; Tchantchaleishvili V
    Artif Organs; 2022 Aug; 46(8):1616-1625. PubMed ID: 35315092
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Hemocompatibility of Axial Versus Centrifugal Pump Technology in Mechanical Circulatory Support Devices.
    Schibilsky D; Lenglinger M; Avci-Adali M; Haller C; Walker T; Wendel HP; Schlensak C
    Artif Organs; 2015 Aug; 39(8):723-8. PubMed ID: 26234452
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Factors Related to Pump Thrombosis With the Heartmate II Left Ventricular Assist Device.
    Klodell CT; Massey HT; Adamson RM; Dean DA; Horstmanshof DA; Ransom JM; Salerno CT; Cowger JA; Aranda JM; Chen L; Long JW; Dembitsky W
    J Card Surg; 2015 Oct; 30(10):775-80. PubMed ID: 26283153
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Results of the European clinical trial of Arrow CorAide left ventricular assist system.
    Saeed D; Arusoglu L; Gazzoli F; Hetzer R; Morshius M; Alloni A; Viganò M; Koerfer R; Golding LA; El Banayosy A
    Artif Organs; 2013 Feb; 37(2):121-7. PubMed ID: 23043450
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Retrospective 1-year outcome follow-up in 200 patients supported with HeartMate 3 and HeartWare left ventricular assist devices in a single centre.
    Mueller M; Hoermandinger C; Richter G; Mulzer J; Tsyganenko D; Krabatsch T; Starck C; Stein J; Schoenrath F; Falk V; Potapov E
    Eur J Cardiothorac Surg; 2020 Jun; 57(6):1160-1165. PubMed ID: 32298426
    [TBL] [Abstract][Full Text] [Related]  

  • 80. COMPETENCE Trial: The EVAHEART 2 continuous flow left ventricular assist device.
    Allen SR; Slaughter MS; Ahmed MM; Bartoli CR; Dhingra R; Egnaczyk GF; Gulati SK; Kiernan MS; Mahr C; Meyer DM; Motomura T; Ono M; Ravichandran A; Shafii A; Smith J; Soleimani B; Toyoda Y; Yarboro LT; Dowling RD
    J Heart Lung Transplant; 2023 Jan; 42(1):33-39. PubMed ID: 36347767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.